Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer

The response rate for osimertinib is high among patients with untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). However, there exist no biomarkers to predict the efficacy of the same. This study investigated whether BIM-γ mRNA expression in circu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory investigation 2021-07, Vol.59 (4), p.535-544
Hauptverfasser:	Isobe, Kazutoshi, Yoshizawa, Takahiro, Sekiya, Muneyuki, Miyoshi, Shion, Nakamura, Yasuhiko, Urabe, Naohisa, Isshiki, Takuma, Sakamoto, Susumu, Takai, Yujiro, Tomida, Taichiro, Adachi-Akahane, Satomi, Iyoda, Akira, Homma, Sakae, Kishi, Kazuma
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Aniline Compounds BIM-γ Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics CTC Epidermal growth factor receptor ErbB Receptors - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Neoplasm Recurrence, Local Neoplastic Cells, Circulating Non-small cell lung cancer Osimertinib Protein Kinase Inhibitors RNA, Messenger - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!